Loading
Mabswitch
Mabswitch is a Los Angeles-area company making antibodies whose strength of binding can be turned up or down by a second, small molecule after they are given. It is applying the idea to CAR-T cells and antibody-drug conjugates for cancer.
Also called: MabSwitch, Inc.
Overview
MabSwitch, Inc. develops ligand-programmable antibodies designed to give control over their activity after administration, and applies them to switchable-affinity T-cell engagers, antibody-drug conjugates and CAR-T cells, according to its website. In 2026 it received two National Cancer Institute SBIR awards: one for a remote-controlled peptide-centric CAR T-cell therapy for solid tumours, whose abstract names neuroblastoma as an example of a low-mutational-burden cancer, and one for an affinity-tunable antibody-drug conjugate against high-grade serous ovarian cancer. All of its programmes are preclinical.
Headquarters
Van Nuys, CA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R43) award 1R43CA310118-01: Remote-Controlled PC-CAR T-Cell Therapy for Hard-to-Treat Solid Tumors | 2026 | $400K | reporter.nih.gov |
| Grant · NCI SBIR (R43) award 1R43CA314526-01: Affinity-tunable Antibody Drug Conjugate (ADC) against High-Grade Serous Ovarian Cancer | 2026 | $400K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
- Company website (home and pipeline pages) and the NIH RePORTER records read on 4 November 2026. No named product candidate is given on the website.
Connected
8Similar pages
- TrialInterleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
Shares Neuroblastoma (paediatric), Ovarian cancer.
- PersonRobbie G. Majzner
- CompanyExpression Therapeutics
Shares Neuroblastoma (paediatric), T-cell engagers (bispecific).
- TargetTNC
Shares Neuroblastoma (paediatric), Ovarian cancer.
- TechnologySafety-switch (suicide gene) CAR-T
- TrialSodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Shares Neuroblastoma (paediatric), Ovarian cancer.
- IdeaGD2 CAR-T as consolidation in high-risk neuroblastoma
- PersonCrystal L. Mackall
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
mabswitch.com · 2
A source that has moved or gone is reported by the weekly link check. /audit/